GlassScriptPhysician profile
Jamie Routman
NPI 1275854812
$2,241.40
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $477 · 2021: $632 · 2022: $523 · 2023: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.59 | 2019-2022 | |
| Novo Nordisk INC | $377.44 | 2019-2023 | Wegovy |
| Astellas Pharma US INC | $161.89 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $156.51 | 2019-2022 | |
| Myovant Sciences INC. | $145.45 | 2021-2022 | |
| Lupin INC. | $129.69 | 2019-2020 | |
| Hologic Sales and Service, LLC | $106.07 | 2019-2022 | |
| Therapeuticsmd, INC. | $79.62 | 2019-2021 | |
| Coopersurgical, INC. | $70.64 | 2019-2021 | |
| Scynexis, INC. | $56.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.80 | 2019-2022 | |
| Minerva Surgical, INC | $46.23 | 2020-2023 | |
| Eisai INC. | $43.76 | 2020-2021 | |
| Evofem Biosciences, INC. | $39.46 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $33.43 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.74 | 2019-2020 | |
| Exeltis, USA INC. | $28.80 | 2020 | |
| Axonics, INC. | $20.79 | 2023 | Axonics |
| Organon LLC | $20.50 | 2022 | |
| Sumitomo Pharma America, INC. | $19.11 | 2023 | Myfembree |
| Mission Pharmacal Company | $18.00 | 2019 | |
| Sage Therapeutics, LLC | $17.33 | 2020 | |
| Shield Therapeutics INC | $17.27 | 2023 | Accrufer |
| Duchesnay USA Incorporated | $14.84 | 2019 | |
| Orexo US, INC. | $14.74 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.35 | 2022 | |
| Becton, Dickinson and Company | $13.65 | 2020 | |
| Currax Pharmaceuticals LLC | $13.44 | 2020 | |
| Medicem INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Routman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.